Artificial intelligence is already quietly embedded in the medical imaging chain. When a radiologist opens a chest X-ray, a mammogram, or an MRI on their workstation today, there is a good chance an algorithm has already looked at it first — flagging a suspicious shadow, measuring a tumour’s volume, or bumping an urgent case to the top of the queue. AI is not replacing doctors, but it is becoming their most tireless assistant.

This explainer looks at what AI actually does in medical diagnosis today, where the evidence for it stands, and where it still falls short.

What AI actually does when it reads a scan

Radiology was a natural first frontier for medical AI because imaging is digital data that computers can process. Most clinical systems today are not designed to hand down a diagnosis on their own. They are built to flag, measure, and prioritise — then hand the result to a radiologist for the final read.

Three jobs dominate current use. First, interpretation support: highlighting suspicious areas — a possible lung nodule on a chest CT, a fracture on an X-ray — so they do not get overlooked. Second, measurement and comparison: sizing tumours or organs more consistently than a human eye can, and tracking changes between scans over time. Third, triage: automatically flagging urgent findings such as strokes, pulmonary embolisms, or internal bleeding so the most critical cases are reviewed first instead of waiting in line.

Patients should understand a key fact: in routine clinical care, AI does not make the diagnosis on its own. A radiologist or qualified doctor reviews the images, considers the patient’s symptoms and history, and produces the final report. AI is a decision-support tool — a second set of eyes.

How the systems are trained

These systems are typically built on deep-learning models trained on large collections of labelled medical images — in some research programmes, millions of them. The algorithm learns to recognise visual patterns associated with normal and abnormal tissue, and outputs probability scores or annotated overlays.

One of the larger published efforts came from a collaboration between the University of Warwick, King’s College London, and several NHS sites. Their AI was trained on 2.8 million historic chest X-rays from more than 1.5 million patients and learned to scan for 37 possible conditions. When its findings were cross-checked by senior radiologists on a sample of over 1,400 X-rays, the AI matched or beat the original doctor’s accuracy for 35 of the 37 conditions — about 94 per cent — and also learned to flag more urgent conditions for faster review.

Where AI matches doctors — and where it helps most

In breast imaging, one of the most-cited demonstrations comes from a 2025 study published in the journal Radiology, in which researchers at Massachusetts General Hospital tested an AI retrospectively against 224 breast cancers that had been missed on earlier screening exams. The algorithm correctly flagged and localised nearly a third of those missed cancers — 32.6 per cent. That is not the AI catching everything; it is the AI catching some of what busy radiologists reasonably missed the first time.

For prostate MRI, a meta-analysis pooling ten studies and more than 20,000 patients found AI performing comparably to radiologists at detecting clinically significant cancer: sensitivity of 0.87 for AI versus 0.85 for radiologists, and specificity of 0.61 versus 0.63 — essentially no meaningful difference between the two. Comparable, not superior, is still notable for a technology that was largely a research curiosity a decade ago.

The area where AI has gone furthest into independent use is diabetic retinopathy screening. Systems such as IDx-DR were cleared by regulators as the first autonomous AI diagnostics — the software itself makes the screening determination, enabling eye-disease screening in primary-care clinics rather than only at specialist centres. More such clearances have followed: in July 2026, the FDA granted 510(k) clearance to iHealthScreen’s iPredict-DR for detecting more than mild diabetic retinopathy (mtmDR), the latest in a growing group of approved AI screening tools.

The regulatory path: software as a medical device

AI diagnostic tools are regulated as medical devices — in regulatory language, “Software as a Medical Device” (SaMD). Before deployment, they must be tested for accuracy and cleared or approved by health authorities, and many are cleared only for use with specific camera or scanner platforms, since the training data may not generalise to equipment the model has never seen.

This regulatory framing matters because it sets the terms of trust. A cleared system has passed formal accuracy testing on defined patient populations — but clearance is a statement about performance under those tested conditions, not a guarantee of flawless behaviour everywhere.

The risks and open questions

Health authorities and researchers are candid about the caveats. Errors still happen: AI models can miss findings or raise false alarms, and systems trained mostly on images from one population or one type of equipment may perform worse elsewhere — a problem known as bias.

There is also the phenomenon of hallucination in general-purpose generative AI models — systems that can produce confident, detailed-sounding medical interpretations without true understanding of an image. Researchers have flagged this as a reason such models need the guardrails that purpose-built diagnostic systems carry.

What comes next

The trajectory points toward broader integration: AI woven into reporting workflows, auto-generating structured summaries; screening extended into primary care for conditions like macular degeneration and glaucoma; and eventually, perhaps, a single retinal-imaging encounter that can reliably screen for several causes of vision loss at once.

FAQs

Can AI diagnose disease on its own?
In most clinical settings today, no — current imaging AI is used as a decision-support tool, with a qualified doctor producing the final report. The exception is a small number of cleared autonomous screening systems, such as those for diabetic retinopathy, where the AI itself makes the screening determination within defined conditions.

Is AI more accurate than doctors?
Sometimes comparable, sometimes slightly better, sometimes worse — it depends on the task and the data. The fairest reading of current evidence is that AI is a strong second reader that catches some of what humans miss, and that its biggest value may be in consistency, speed, and access rather than raw superiority.

Will AI replace radiologists?
There is no credible evidence of that happening. Modern imaging produces enormous volumes of detailed data, and AI’s proven role is handling selected tasks — flagging, measuring, prioritising — while radiologists integrate images with clinical context that AI cannot see. Health authorities consistently frame AI as support, not substitution.

What are the main risks patients should know about?
AI can make mistakes, may perform unevenly across populations or equipment, and raises privacy questions around training data. That is why regulators require formal accuracy testing before clinical use, and why the human doctor remains the final arbiter.

Compiled by the Khabar 24h Editorial Desk from publicly available sources.